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Abstract
The clinical management of pancreatic ductal adenocarcinoma
(PDAC) is hampered by the lack of reliable biomarkers. This study
investigated the value of soluble stroma-related molecules as
PDAC biomarkers. In the first exploratory phase, 12 out of 38 mole-
cules were associated with PDAC in a cohort of 25 PDAC patients
and 16 healthy subjects. A second confirmatory phase on an inde-
pendent cohort of 131 PDAC patients, 30 chronic pancreatitis
patients, and 131 healthy subjects confirmed the PDAC association
for MMP7, CCN2, IGFBP2, TSP2, sICAM1, TIMP1, and PLG. Multivari-
able logistic regression model identified biomarker panels discrimi-
nating respectively PDAC versus healthy subjects (MMP7 + CA19.9,
AUC = 0.99, 99% CI = 0.98–1.00) (CCN2 + CA19.9, AUC = 0.96,
99% CI = 0.92–0.99) and PDAC versus chronic pancreatitis
(CCN2 + PLG+FN+Col4 + CA19.9, AUC = 0.94, 99% CI = 0.88–0.99).
Five molecules were associated with PanIN development in two
GEM models of PDAC (PdxCre/LSL-KrasG12D and PdxCre/
LSL-KrasG12D/+/LSL-Trp53R172H/+), suggesting their potential for
detecting early disease. These markers were also elevated in
patient-derived orthotopic PDAC xenografts and associated with
response to chemotherapy. The identified stroma-related soluble
biomarkers represent potential tools for PDAC diagnosis and for
monitoring treatment response of PDAC patients.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most
aggressive epithelial malignancies, with a 5-year survival rate of 6%
(Tempero et al, 2013). Although progression from tumor initiation
to advanced invasive cancer may take up to about 10 years
(Yachida et al, 2010), PDAC is often diagnosed at an advanced
stage, because of non-specific symptomatology, the absence of effec-
tive imaging tests to identify early disease, and the lack of specific
and sensitive diagnostic circulating biomarkers (Korc, 2007).
Late diagnosis of PDAC leads to a limited therapeutic time
window during which serological markers capable of monitoring
treatment effectiveness could change the fate of PDAC patients.
The biomarker CA19.9, currently used to detect and monitor
PDAC, is not sufficiently sensitive and specific to have reliable diag-
nostic value. In addition, it is not expressed in approximately 20%
of the Lewis antigen-negative population. There are also racial and
sex variations in CA19.9 expression with the highest levels in
Caucasians (Tempero et al, 2013). Recent proteomic studies have
identified circulating molecules or autoantibodies that are up-regu-
lated in PDAC, but few have been investigated further as a serologi-
cal diagnostic or prognostic biomarker for the disease (Brand et al,
2011; Capello et al, 2013, 2017; Chan et al, 2014; Shaw et al, 2014;
Zhang et al, 2014; Balasenthil et al, 2017).
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PDAC is notable for its desmoplastic stromal reaction and
prominent extracellular matrix (ECM) deposition (Whatcott et al,
2015). Stromal elements and extracellular matrix remodeling
have a role in PDAC progression and, ultimately, chemotherapy
delivery and activity (Feig et al, 2012). The microenvironment
changes from normal to a tumor-supportive state, favoring tumor
growth and invasion. It has been suggested that desmoplasia
might have a prognostic role since fibrosis, stromal abundance,
and reactivity have been correlated with shorter survival in
patients with resected PDAC (Erkan, 2013). The abundant stroma
is one of the main reasons for the limited drug response of
PDAC (Neesse et al, 2011).
Based on these observations, we hypothesized that the tumor
microenvironment might be a source of circulating molecules
exploitable as diagnostic biomarkers and as endpoints of target ther-
apies. Since stromal modifications occur early in tumorigenesis and
persist in advanced tumors, stroma-related circulating molecules
might have great potential for the diagnosis of PDAC identified at a
stage in which the disease is still operable.
In this study, we combined multiple approaches to investigate
circulating stroma-related molecules as PDAC diagnostic biomark-
ers and as endpoints for assessing the effectiveness of treatment.
Thirty-eight stroma-associated potential circulating biomarkers,
including extracellular matrix proteins and proteolytic fragments,
matrix-degrading enzymes and their inhibitors, growth factors,
antiangiogenic factors, and adhesion molecules, were selected
from previous proteomic analyses (Yu et al, 2005; Bloomston
et al, 2006; Faca et al, 2008; Kojima et al, 2008; Fiedler et al,
2009; Rong et al, 2010; Xue et al, 2010; Pan et al, 2011) and
measured in the plasma of PDAC patients, healthy controls, and
chronic pancreatitis patients. Selected candidate molecules were
further validated in genetically engineered mouse models of
PDAC with mutated Kras (KC mice) or with mutated Kras and
TP53 (KPC mice) and associated with PDAC initiation and
progression (PanIN-PDAC) (Hingorani et al, 2003, 2005; Capello
et al, 2013), as well as in patient-derived PDAC xenografts
(PDAC-PDX), where their levels correlated with tumor burden
and response to treatment.
Results
Selection of candidate PDAC stroma-related biomarkers
Tumor-stroma-associated PDAC biomarkers were selected from
eight proteomic studies on circulating proteins that are differen-
tially expressed in PDAC and healthy subjects (Yu et al, 2005;
Bloomston et al, 2006; Faca et al, 2008; Kojima et al, 2008;
Fiedler et al, 2009; Rong et al, 2010; Xue et al, 2010; Pan et al,
2011). Thirty-eight candidates were selected because they were
found in at least two independent analyses and/or were related
to tumor/stroma interaction by Gene Ontology. These data
were integrated with manually curated additional information
from the literature. The selected molecules are listed in
Table EV1 and include extracellular matrix proteins and prote-
olytic fragments, matrix-degrading enzymes and their inhibitors,
growth factors, angiogenesis regulatory factors, and adhesion
molecules.
Analysis of circulating PDAC stroma-related biomarkers
in patients
First exploratory phase
The levels of the 38 selected candidate biomarkers were analyzed in
the plasma of patients with histologically verified PDAC (n = 25)
and in healthy controls (n = 16) (cohort no. 1 in Table 1). The
concentrations are shown in Table EV2.
We identified six clusters of biomarkers that are as correlated as
possible with each other and as uncorrelated as possible with
biomarkers in other clusters (Table 2). The plasma levels of the
molecules in these clusters are shown in Fig 1. At univariate logistic
regression, three clusters (clusters 3, 4, and 6) were significantly
associated with the presence of PDAC (respectively P = 0.007,
P = 0.005, and P = 0.07).
Molecules in these clusters (with the exception of Lam-P1 for
which commercially available kits had been discontinued) were
selected for further analysis.
Second confirmatory phase
Molecules in clusters 3, 4, and 6 (TIMP1, sICAM1, MMP7, PICP,
PLG, TSP2, IGFBP2, FN, PINP, CCN1, CCN2, Col4) were further
analyzed in a larger independent cohort of PDAC patients
(n = 131), pancreatitis patients (n = 30), and sex-matched healthy
individuals (n = 131) (cohort no. 2 in Table 1). The distribution of
the twelve molecules in the second cohort of patients is shown in
Table EV3.
Seven (TIMP1, sICAM1, MMP7, TSP2, PLG, IGFBP2, and CCN2)
of the 12 molecules were significantly up-regulated in PDAC patients
compared to healthy controls (P < 0.001) (Fig 2A; Tables EV3 and
EV4). The differences between PDAC and healthy subjects were
excellent for MMP7 (AUC = 0.98) and good for CCN2 (AUC = 0.86),
which demonstrated a discriminatory ability similar to CA19.9
(AUC = 0.87), while IGFBP2 and TIMP1 (AUC = 0.82), TSP2
(AUC = 0.78), sICAM1 (AUC = 0.77), and PLG (AUC = 0.66) had a
weaker discriminatory ability (Fig EV1 and Table EV4). The seven
molecules were confirmed to be significantly up-regulated also at
early stages (stages IA, IB, and IIA) when tumor is confined to the
pancreas and is not spread to nearby lymph nodes (N0) or to distant
Table 1. Clinical characteristics of the study population.
Number
of cases
Gender
(%)
Age median
(Range)
PDAC
stage (%)
Cohort 1 (Exploratory phase)
Healthy n = 16 M (62.5)
F (37.5)
59 (54–65) Stage IA (16)
Stage IIA (24)
Stage IIB (56)
ND (4)
PDAC n = 25 M (40)
F (60)
50 (47–82)
Cohort 2 (Confirmatory phase)
Healthy n = 131 M (49.6)
F (50.4)
55 (44–66) Stage IA (1.5)
Stage IB (0.8)
Stage IIA (16.8)
Stage IIB (66.4)
Stage III (0.8)
Stage IV (2.3)
ND (11.4)
Chronic
pancreatitis
n = 30 M (73.3)
F (26.7)
53 (34–79)
PDAC n = 131 M (49.6)
F (50.4)
70 (38–88)
ND, not determined; M, males; F, females.
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sites (M0). AUCs used to estimate the predictive accuracy of distri-
butional models did not change significantly between stages
(Fig EV1 and Appendix Table S2). Age difference between PDAC
patients and healthy individuals did not affect the significant associ-
ation between each selected biomarker and PDAC, as assessed by a
multivariable logistic regression model, adjusted for age effect (data
not shown). No correlation was found between these molecules and
CA19.9 (Appendix Fig S1).
Cohort no. 2 also included 30 patients with chronic pancreatitis
(CP). The levels of TIMP1, sICAM1, MMP7, IGFBP2, CCN2, and
TSP2, though lower than in PDAC, were increased in plasma from
CP compared with healthy controls. Significantly lower levels of
Col4 and FN were specifically associated with CP (P < 0.001). PLG
in CP was significantly lower than in PDAC (P < 0.001), but not
significantly different from healthy subjects (P < 0.05) (Fig 2A and
Table EV4).
Using a multivariable logistic regression model, we then
developed biomarker panels that improved the discovery power of
CA19.9 in PDAC versus healthy subjects and PDAC versus CP. In
accordance with the statistical procedure adopted, the resulting
panel consisting of MMP7 and CA19.9 statistically better discrimi-
nated PDAC versus healthy subjects with an AUC of 0.99 (99%
CI = 0.98–1.00) compared with CA19.9 (AUC = 0.87, 99%
CI = 0.81–0.93). Similarly, the panel consisting of CCN2 and
CA19.9 with an AUC of 0.96 (99% CI = 0.92–0.96) discriminated
PDAC versus healthy subjects better than CA19.9 (Fig 2B).
Multivariable models defined in the overall population were evalu-
ated by stage. As reported in Appendix Table S2, they confirmed
their optimal predictive accuracy without significant interaction
between stages.
A panel consisting of CCN2, PLG, FN, Col4, and CA19.9
improved the performance of CA19.9 in distinguishing PDAC from
CP. These five biomarkers, which individually (Table EV4) had an
AUC of 0.56 (99% CI = 0.41–0.71, CCN2), 0.74 (99% CI = 0.61–
0.86, PLG), 0.80 (99% CI = 0.65–0.94, FN), 0.74 (99% CI = 0.59–
0.89, Col4), and 0.83 (99% CI = 0.75–0.92, CA19.9), when analyzed
in combination showed an AUC of 0.94 (99% CI = 0.88–0.99) indi-
cating a significantly higher capability to discriminate PDAC from
CP (Fig 2B). Similar results were obtained separating PDAC by
stages (Appendix Table S2).
Circulating stroma-related molecules in mouse models
of PDAC
High TIMP1, MMP7, TSP2, CCN2, and ICAM1 in KrasG12D- and
p53R172H-driven PanIN development
We used KC mice expressing the mutation of Kras (KrasG12D) in
pancreatic progenitor cells and progressing from a healthy
condition to different grades of PanIN (PanIN-1A–1B–2–3) (Hingo-
rani et al, 2003; Cappello et al, 2013) and KPC mice, carrying
KrasG12D/+ and p53R172H/+ mutations and developing PanINs that
ultimately progresses to overt carcinoma (Hingorani et al, 2005)
to study the importance of the selected biomarkers during PDAC
induction.
Plasma was collected at 60, 120, 180, 240, and 330 days of age
from KC mice and at 30, 90, and 150 days of age from KPC mice.
We measured those biomarkers for which reliable ELISA was
commercially available.
Plasma TIMP1, MMP7, and TSP2 levels rose significantly over
time in relation to PanIN development in both KC and KPC mice
(Fig 3A). At death of KC mice on day 330, when histological analy-
sis of the pancreas confirmed the presence of PanIN-1A, PanIN-1B,
and PanIN-2 in, respectively, 2, 2, and 4 lesions (Appendix Fig
S2A), MMP7 and TSP2 plasma levels were significantly higher than
control PdxCre mice (Fig 3B; KC).
TIMP1, MMP7, and TSP2 levels were also significantly higher in
KPC than PdxCre mice at 150 days of age (Fig 3B; KPC).
None of the three molecules were elevated in the plasma of mice
with caerulein-induced chronic pancreatitis after 7 weeks of treat-
ments confirming the specific association of high levels of TIMP1,
MMP7, and TSP2 with neoplastic transformation (Fig 3B and
Appendix Fig S3).
Pancreatic RNA expression analysis was performed for CCN2,
IGFBP2, ICAM1, and PLG for which ELISA kits to measure mouse
proteins were not available, and for TIMP1, MMP7, and TSP2.
Real-time PCR with mouse-specific probes showed that TIMP1,
MMP7, TSP2, CCN2, and ICAM1 (P < 0.05) were more expressed
Table 2. Clusters of biomarkers associated with PDAC.
Cluster
No. Molecules Ro
2a Rn
2b
(1 - Ro
2)/
(1 - Rn
2)
ratio P valuec
1 MMP12 0.810 0.087 0.208 0.364
MMP13 0.790 0.117 0.238
IGFBP4 0.864 0.316 0.199
IGFBP5 0.726 0.266 0.373
SPARC 0.656 0.206 0.433
2 ES 0.581 0.086 0.459 0.176
PDGF-BB 0.776 0.253 0.299
FGF-2 0.848 0.087 0.166
VEGFA 0.948 0.098 0.057
3 TIMP1 0.836 0.181 0.200 0.007
sICAM1 0.535 0.210 0.588
MMP7 0.648 0.056 0.373
PICP 0.244 0.067 0.810
PLG 0.249 0.126 0.859
TSP2 0.772 0.333 0.342
4 IGFBP2 0.573 0.232 0.556 0.005
FN 0.231 0.053 0.812
PINP 0.121 0.024 0.900
CCN1 0.587 0.294 0.585
CCN2 0.627 0.097 0.413
5 sVCAM1 0.606 0.042 0.412 0.332
NGAL 0.606 0.024 0.404
6 Col4 0.715 0.085 0.311 0.070
Lam-P1 0.715 0.063 0.304
aSquared correlation coefficient between a given biomarker and its own
cluster.
bThe next highest squared correlation coefficient between a given biomarker
and any other cluster.
cP value from 1 df Wald v2 for association with outcome.
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in KC than in control PdxCre mice at 330 days of age (Appendix
Fig S2B). TIMP1, MMP7, TSP2, and CCN2 expression in PanIN
lesions was confirmed by immunohistochemistry. TIMP1, MMP7,
TSP2, and CCN2 staining was typically low in PdxCre pancreas,
while a more intense staining was observed in PanIN lesions
(Fig 3C).
TIMP1, MMP7, TSP2, CCN2, and ICAM1 are elevated in mice with
patient-derived PDAC xenografts
We measured TIMP1, MMP7, and TSP2 using mouse-specific
ELISA in three PDAC-PDX (HuPa4, HuPa8, and HuPa11) growing
orthotopically in the pancreas of SCID mice. These tumors are
characterized by relevant amounts of host murine stroma
(Appendix Fig S4) supporting their use for stroma-derived
biomarker validation. In all the PDAC-PDX models, circulating
mouse TIMP1, MMP7, and TSP2 levels were significantly higher
than in healthy mice (P < 0.05) (Fig 4A) paralleling the tumor
growth in the pancreas as shown by the significant correlation
with tumor burden measured by MRI (TIMP1, r = 0.68; MMP7,
r = 0.60 and TSP2, r = 0.82) (Fig 4B).
TIMP1, TSP2, and CCN2 but not MMP7 mRNA was highly
expressed in HuPa4, HuPa8, and HuPa11 (PDAC-PDX versus healthy
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Figure 1. Phase I exploratory phase (cohort no. 1): plasma levels of molecules belonging to PDAC-associated clusters.
Plasma levels of the 13 biomarkers belonging to clusters 3, 4, and 6 (see Table 2) in healthy subjects (n = 16) and PDAC patients (n = 25), *P < 0.01 (Mann–Whitney). Data are
expressed as a scatter plot, mean  SEM. P-values (for each cluster) were calculated with the Wilcoxon rank-sum test and indicate a significant association between each
cluster and PDAC.
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mice P < 0.05) (Fig 4C). In agreement, immunohistochemical analy-
sis highlighted a strong expression of TIMP1, TSP2, and CCN2
proteins in the tumor stroma (Fig 4D). ICAM1 was more expressed in
all the three PDAC-PDX compared to healthy mice (P < 0.05) while
IGFBP2 mRNA levels were significantly higher only in HuPa4
(P < 0.05), and PLG was not increased in PDAC-PDX (Fig 4C).
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Figure 2. Phase II confirmatory phase (cohort no. 2): plasma levels and AUC values of selected molecules.
A Plasma levels of selected candidate biomarkers analyzed in healthy subjects (n = 131), pancreatitis patients (n = 30), and PDAC patients (n = 131). Data are expressed
as a scatter plot, mean  SEM, *P < 0.001 (Wilcoxon rank-sum test).
B Receiver operator characteristic (ROC) curves of the single biomarkers and of biomarker panels (indicated with All) for diagnosis of PDAC versus healthy controls and
PDAC versus pancreatitis. Areas under the curve (AUC) with 99% CI are presented.
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TIMP1, MMP7, and TSP2 as biomarkers of treatment response in
PDAC-PDX models
TIMP1, MMP7, and TSP2 increased over time in plasma of mice
bearing HuPa8 (Fig 5A). To analyze the relevance of the selected
stroma-related molecules as markers of drug response, we treated
HuPa8-bearing mice with gemcitabine monotherapy or combined
with albumin-bound paclitaxel (NAB-P) to reproduce clinical studies
(Von Hoff et al, 2013; Goldstein et al, 2015).
Gemcitabine as single agent had no worthwhile effect on HuPa8
growing in the mouse pancreas, but the combination with NAB-P
significantly inhibited tumor growth (Fig 5B and C).
TIMP1, MMP7, and TSP2 were measured before, during, and
after treatments (Fig 5D). Their plasma levels reflected tumor
response to treatment, matching the tumor burden changes
measured by MRI over time. Differences in the biomarker plasmatic
levels became evident after four treatments, paralleling treatment
response. After eight treatments, TIMP1, MMP7, and TSP2 were
significantly lower (P < 0.05) in the responding (gemcitabine +
NAB-P group) compared to the non-responding tumors (gemcitabine
group), thus suggesting they were potential markers for monitoring
tumor response and treatment efficacy.
Discussion
Tumor progression relies on the creation of a favorable microenvi-
ronment involving not only cancer cells, but also stroma and
immune/inflammatory cells. This is particularly true for PDAC
(Erkan, 2013). The critical roles of stroma and extracellular matrix
remodeling in determining PDAC initiation, growth, and metastasis
and in hampering drug response have suggested possibilities for
using stroma-related molecules as diagnostic and prognostic
biomarkers. This study identified seven stroma-related biomarkers
for PDAC and three biomarker panels able to distinguish PDAC
patients from healthy individuals or from pancreatitis patients.
In an initial search, we selected 38 stroma-related molecules
from proteomic studies because of their strong relevance in tumor/
stroma interaction. The individual relationship of each of these
molecules with PDAC has previously been shown (Lekstan et al,
2012; Park et al, 2012; Nixon et al, 2013; Poruk et al, 2014; Jenkin-
son et al, 2015); however, our study is the first one to measure and
compare all these molecules together in order to select the best
candidate biomarkers. From this large number of candidates,
TIMP1, sICAM1, MMP7, IGFBP2, CCN2, TSP2, and PLG emerged as
PDAC biomarkers, being associated with the presence of PDAC in
two independent cohorts of patients and two autonomous sequen-
tial analyses.
The fact that in the second confirmatory phase the seven selected
molecules were significantly higher in PDAC patients than in healthy
individuals validates the statistical approach based on the clustering
method used in the first exploratory phase of the study. Here, the prin-
cipal components-based clustering method used (Black & Watanabe,
2011) was chosen as a data reduction method to control type I and
type II error rates better than univariate analysis of individual mark-
ers, when analyzing multiple molecules in a small cohort of patients.
Multivariable logistic regression model identified MMP7 plus
CA19.9 and CCN2 plus CA19.9 as the circulating biomarker panels
that better discriminate PDAC patients from healthy subjects.
MMP7, also known as matrilysin, is a well-established inducer of
acinar-to-ductal metaplasia (Crawford et al, 2002; Sawey et al,
2007), and it was found focally up-regulated in PanIN lesions of the
Kras-driven GEM model of PDAC (Hingorani et al, 2003). Although
MMP7 involvement in PDAC initiation and progression has been
reported (Fukuda et al, 2011), our results showing high MMP7
plasma levels in association with early tumor progression in PDAC-
GEM models and in patients with PDAC at stages IA, IB, and IIA
confirm its value as a potential early diagnostic biomarker. CCN2,
also known as connective tissue growth factor (CTGF), is overex-
pressed by activated pancreatic stellate cells in the earliest stages of
PDAC. It promotes local desmoplasia, tumor survival, and metasta-
sis (Leask, 2009). Soluble CCN2 in plasma, serum, and urine has
promising applicability as biomarker in different types of chronic
diseases with fibrosis-related complications (Dendooven et al,
2011). While CCN2 has been shown up-regulated in PDAC tumors,
◀ Figure 3. Biomarkers in PdxCre/LSL-KrasG12D (KC) and KrasG12D/Trp53R172H (KPC) GEM models.A Levels of TIMP1, MMP7, and TSP2 in plasma of KC mice (n = 7–9) at 60, 120, 180, 240, and 330 days of age and of KPC mice (n = 3–8) at 30, 90, and 150 days of age
(mean  SEM). *P < 0.05 (Mann–Whitney). The exact n and P-values are indicated in Appendix Table S3A.
B Levels of TIMP1, MMP7, and TSP2 in plasma of healthy mice (n = 15), mice with chronic pancreatitis at 150 days of age (n = 19), KC mice at 330 days of age (control
PdxCre n = 3–4; KC n = 7–8), and KPC mice at 150 days of age (control PdxCre n = 4–7; KPC n = 4). The exact n is indicated in Appendix Table S3B. Box plots extend
from 25th to 75th percentiles, whiskers extend from min to max, and horizontal lines indicate median. P-values were calculated with one-way ANOVA with Tukey’s
multiple comparison test.
C Histological analysis of pancreas from PdxCre and KC mice with different grades of PanIN lesions at 330 days of age. Anti-TIMP1, anti-MMP7, anti-TSP2, and anti-
CCN2 staining of a representative KC PanIN lesion (200×, scale bars: 100 lm).
▸Figure 4. Biomarkers in PDAC-PDX growing orthotopically in mouse pancreas.A Levels of murine TIMP1, MMP7, and TSP2 in plasma of mice bearing PDAC-PDX (HuPa4, HuPa8, and HuPa11) growing orthotopically in the pancreas (mean  SEM;
n ≥ 3 for each group), *P < 0.05 (Mann–Whitney). The exact n and P-values are indicated in Appendix Table S4A.
B Correlations between the levels of the three selected biomarkers and the tumor volume in mice bearing HuPa8. Pearson coefficient (r).
C Expression of murine TIMP1, MMP7, TSP2, CCN2, ICAM1, IGFBP2, and PLG analyzed in tumors from pancreas (HuPa4, HuPa8, and HuPa11) by RT–PCR. The expression
level of target genes was normalized to the geometric median of b-actin and GAPDH housekeeping genes and expressed as 2-DDCT (mean  SEM, *P < 0.05; Healthy
n = 7; HuPa4, HuPa8, and HuPa11 n = 4) (Mann–Whitney). The exact P-values are indicated in Appendix Table S4B.
D Histological analysis of representative PDAC-PDX (HuPa4, HuPa8, and HuPa11). Hematoxylin–eosin, anti-TIMP1, anti-MMP7, anti-TSP2, and anti-CCN2 staining of
PDAC-PDX tumors (200×, scale bars: 100 lm).
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our study for the first time demonstrates its utility as a circulating
PDAC biomarker in patients (Bennewith et al, 2009; Neesse et al,
2011).
Both MMP7 and CCN2 have been associated with poor progno-
sis in different types of cancer (Klupp et al, 2016; Sun et al, 2017)
and with fibrotic or inflammatory diseases (Dendooven et al, 2011;
Irvine et al, 2016). However, our results suggest that an improve-
ment in the specificity of MMP7 and CCN2 results from the inclu-
sion of additional biomarkers. In particular, it needs to be
emphasized that the proposed panels of molecules confirmed
A
B
D
C
Figure 5. Murine circulating TIMP1, MMP7, and TSP2 as biomarkers of treatment response in PDAC-PDX models.
Responsiveness to gemcitabine (GEM), either alone or combined with Nab–paclitaxel (NAB-P), was evaluated in mice bearing orthotopic HuPa8 in the pancreas. Nab–
paclitaxel (25 mg/kg) and gemcitabine (150 mg/kg) were given i.v. on days 1 and 8 of each 21-day cycle (for a total of 8 treatments).
A Levels of TIMP1, MMP7, and TSP2 in plasma of mice bearing orthotopic HuPa8 at 30, 90, and 150 days after tumor transplantation (mean  SEM; n ≥ 4 for each
group). *P < 0.05 (Mann–Whitney). The exact n and P-values are indicated in Appendix Table S5A.
B Magnetic resonance imaging of HuPa8. Representative images are shown; the white dotted lines indicate tumor masses.
C Tumor growth over time measured by MRI; each black arrow indicates one treatment (mean  SEM; n = 4 for each group; two-way ANOVA with Tukey’s multiple
comparison test).
D Levels of the three selected biomarkers in plasma of HuPa8-bearing mice, prior to (day 80; at randomization), during (day 120), and after (day 165) treatments
(mean  SEM; n ≥ 4 for each group; two-way ANOVA with Tukey’s multiple comparison test). The exact n is indicated in Appendix Table S5B.
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greater potential as diagnostic biomarkers for PDAC than any
single molecule. MMP7 and CCN2 complemented well the perfor-
mance of CA19.9 in distinguishing PDAC from healthy subjects.
Further addition of PLG, FN, and Col4 to the CCN2 and CA19.9
panel increased the performance of CA19.9 in distinguishing PDAC
from CP.
The identification of early diagnostic biomarkers for PDAC is
hampered by the fact that most of the clinical samples come from
patients with advanced high-grade lesions. The use of in vivo
preclinical models that faithfully reproduce the complexity of the
stroma in PDAC early development is therefore fundamental for
biomarker discovery and drug testing.
GEM models of PDAC are unique tools to analyze proteins asso-
ciated with pre-neoplastic and early-phase tumors, integrating data
obtained from patients (Ligat et al, 2015). Our findings that tissue
TIMP1, MMP7, TSP2, and CCN2 and plasma TIMP1, MMP7, and
TSP2 were elevated in association with PanIN development, in both
KC and KPC mice, suggest that they appear in the early pre-invasive
stage of the disease and can truly detect PDAC prior to the develop-
ment of clinical symptoms and in lesions with different mutational
status.
The value of TIMP1, MMP7, and TSP2 as circulating biomark-
ers was corroborated in PDAC-PDX-bearing mice where the
plasma levels of these molecules reflected the high levels found
in the corresponding patient’s plasma (data not shown) and
correlated with tumor burden over time. Immunostaining with
specific anti-mouse antibodies and probes allowed to clarify the
origin of these biomarkers and revealed that tissue TIMP1 and
TSP2 paralleled their plasma level. Notably, no increase in MMP7
expression was detected by RT–PCR, suggesting that the increased
levels of MMP7 detected in the plasma of tumor-bearing mice
might reflect a systemic response of the host to the tumor, in line
with the known association of MMP7 with inflammation (Fukuda
et al, 2011).
This also indicates that the host stroma, in both GEM and PDAC-
PDX models, reproduces the complexity of the human PDAC
microenvironment, undergoing a profound re-organization during
tumor progression. Our data in mouse models also indicate that
stroma-derived biomarkers can be useful not only for early detec-
tion, as evidenced in GEM models, but also for monitoring tumor
growth, as evidenced in PDAC-PDX where their levels correlated
with tumor burden.
Chronic pancreatitis (CP) is a risk factor for PDAC in humans
(Lowenfels et al, 1993) and favors the development of PanIN and
PDAC in Kras-driven mouse models (Guerra et al, 2007). The
presence of inflammatory cytokines and high fibrosis create a
permissive microenvironment for PanIN. These common patholog-
ical features justify the high levels of many of our stroma-related
molecules found in the plasma of patients with CP. For example,
MMP7 is activated via the Stat3 pathway in CP and involved in
PDAC initiation and progression in GEM models of PDAC
(Fukuda et al, 2011).
Nonetheless, we found three markers, FN, Col4, and PLG, signifi-
cantly different in PDAC versus pancreatitis. The combination of
these three markers with CCN2 and CA19.9 had a significant capa-
bility to discriminate between PDAC and CP. Notably, herein the
identified CCN2 + PLG+FN+Col4 + CA19.9 panel appeared to have
a higher capability in discriminating PDAC from pancreatitis
(AUC = 0.94) than the recently proposed TIMP1 + LRG1 + CA19.9
panel (AUC = 0.89) (Capello et al, 2017).
Differently from patients, plasma levels of TIMP1, MMP7, and
TSP2 were not increased in the mouse model of caerulein-induced
CP and were significantly lower than PanIN. This might be
explained by the different pathogenic mechanisms causing CP in
patients and mouse model: in patients, usually it takes several years
for permanent changes and CP symptoms to occur, for example,
after a long-standing overuse of alcohol, while in mice CP is phar-
macologically induced and complete damage occurs after few weeks
of caerulein treatment.
Patient-derived tumor xenografts that reproduce the morphologi-
cal and molecular characteristics of the original tumor are being
used for drug development (Tentler et al, 2012; Ricci et al, 2014;
Gao et al, 2015). Here, we show that TIMP1, MMP7, and TSP2
plasma levels correlated with the response to a Nab–paclitaxel–
gemcitabine combined treatment in the PDAC-PDX HuPa8. Stroma-
disrupting effects of Nab–paclitaxel in pancreatic cancer have been
proposed as marker of drug activity (Alvarez et al, 2013). The value
of stroma-related molecules as biomarker of response to drugs,
particularly those expected to modify the tumor microenvironment
(Neesse et al, 2013; Masso-Valles et al, 2015; Hingorani et al,
2016), needs to be further studied.
In conclusion, a PDAC signature of seven circulating stroma-
related molecules has been identified and confirmed in two indepen-
dent cohorts of patients, supporting our hypothesis that stroma
remodeling leads to the release of circulating biomarkers. The asso-
ciation of at least five of them with PanIN in mouse models con-
firmed their potential to detect early lesions. A prospective
confirmatory clinical study is required to characterize them as diag-
nostic PDAC biomarkers complementing CA19.9. Their correlation
with tumor burden and drug response in PDAC-PDX models
suggests they may also be useful as biomarkers for treatment effi-
cacy in patients.
Materials and Methods
Patients
Plasma samples were isolated from peripheral venous blood
collected from two independent cohorts of patients with PDAC diag-
nosed at the Policlinico G.B. Rossi Borgo Roma, Verona (first
exploratory phase), and at the Humanitas Research Hospital,
Rozzano, Milano (second confirmatory phase). Patients’ main char-
acteristics are listed in Table 1. The collection and use of blood
samples was approved by the local scientific ethics committees, and
patients gave written consent. Criteria for inclusion in the study were
as follows: histological diagnosis of PDAC, no previous chemother-
apy, and no history of other invasive cancer. Control groups
consisted of plasma samples from patients with chronic pancreatitis
(CP) and healthy volunteers with no concomitant illnesses. Plasma
samples were aliquoted and stored at 80°C until processing.
Mice and models
Six-week-old female and male PdxCre/LSL-KrasG12D (KC) mice
(Hingorani et al, 2003), PdxCre/LSL-KrasG12D/+/LSL-Trp53R172H/+
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(KPC) mice (Hingorani et al, 2005; Capello et al, 2013), and PdxCre
control mice were maintained at Biogem (Ariano Irpino, Avellino,
IT). Chronic pancreatitis was induced in 10-week-old sex-matched
C57BL/6 mice (Envigo, Correzzana, Italy) as previously described
(Neuschwander-Tetri et al, 2000). Briefly, mice were injected intra-
peritoneally with 50 lg/kg of caerulein (AnaSpec, Fremont, CA,
USA) 6 times over 5 consecutive hours, three times a week for 7
weeks. The severity of acute injury was initially verified by
measuring plasma pancreatic a-amylase using Reflotron tests
(Roche, Mannheim, Germany). Pancreatic tissue atrophy and
fibrosis were detected by Sirius Red staining at sacrifice.
Three patient-derived PDAC xenografts (HuPa4, HuPa8, and
HuPa11) were engrafted in 6- to 8-week-old male severe combined
immunodeficiency (SCID) mice (Envigo, Correzzana, Italy) by
orthotopic intrapancreas transplantation (manuscript in prepara-
tion). The PDAC-PDX models were molecularly and biologically
characterized and found to be similar to the original tumor patient.
PDAC-PDX were used within the third passage after their first
engraftment.
PDAC-PDX growth in the pancreas was monitored by abdominal
palpation and by magnetic resonance imaging (MRI) using 7-Tesla
BioSpec AVIII system (Bruker Biospin). T2-weighted high-resolution
sequences were analyzed using ImageJ software to calculate tumor
volume (Cesca et al, 2016).
Nab–paclitaxel (Abraxane, Celgene; 25 mg/kg i.v.) and gemc-
itabine (Gemcitabina Teva, Teva, 150 mg/kg i.v.) (HDE: 75 and
450 mg/m2, respectively) were given as single treatment or in
combination, on days 1 and 8 of each 21-day cycle for a total of 8
treatments.
Mice were maintained under specific pathogen-free conditions,
housed in isolated vented cages, and handled using aseptic proce-
dures. Procedures involving animals and their care were conducted
in conformity with institutional guidelines that comply with
national (Lgs 26/2014) and EU directives laws and policies (EEC
Council Directive 2010/63), in line with guidelines for the welfare
and use of animals in cancer research (Workman et al, 2010).
Animal studies were approved by the Mario Negri Institute Animal
Care and Use Committee and by Italian Ministry of Health (DM 85/
2013-B and Authorization no. 601/2016-PR).
Biomarker analysis in blood samples
EDTA platelet-poor plasma samples were processed within 30 min
of blood drawing, aliquoted, and stored at 80°C until further use.
Circulating levels of tumor markers were measured using Luminex-
based assays and commercially available ELISA (Millipore S.p.A.,
Vimodrone, Italy; R&D Systems, Inc., Minneapolis, MN, USA;
Cusabio, Wuhan, P.R. China) (Appendix Table S1). Tests were run
according to the manufacturer’s instructions. Each sample was
analyzed in duplicate. Species specificity of the assays for human
and murine analytes was verified by the absence of cross-reactivity
for, respectively, murine and human plasma.
Histological and immunohistochemical analysis
PanIN lesions from GEM and tumor specimens from PDAC-PDX
were collected, fixed in 10% phosphate-buffered formalin, and
embedded in paraffin. Samples were cut into 4-lm-thick sections,
and serial sections from each sample were histochemically stained
with H&E, Alcian Pas, and Sirius Red. Samples from GEM were
histologically classified at the appropriate stage of tumor progres-
sion according to Hingorani et al (2003) and graded by the highest-
grade component of the lesions. For immunohistochemical analysis,
anti-vimentin EPR3776 1:500 (ab92547; Abcam, marker of
mesenchymal cells of both human and murine origin), anti-vimentin
Sp20 1:500 (RM 92120; Thermo Scientific, marker of mesenchymal
cells of human origin), anti-human HLA-A 1:500 (ab52922; Abcam,
marker of cells of human origin), anti-TIMP1 1:300 (AF980; R&D),
anti-MMP7 1:50 (3801S; Cell Signaling), anti-TSP2 1:25 (PA5-50843;
Thermo Scientific), and anti-CCN2 1:100 (ab6992; Abcam) were
used.
Real-time PCR
Total tumor RNA was extracted with TRIzol (Invitrogen), purified,
and then reverse-transcribed with the High-Capacity cDNA Archive
kit (Applied Biosystems, Monza, Italy), according to the manufac-
turer’s instructions. TIMP1, MMP7, TSP2, CCN2, ICAM1, IGFBP2,
and PLG gene expression was analyzed by real-time qRT–PCR using
PrimeTime Gene Expression Master Mix and murine-specific
PrimeTime Std qPCR Assay (Mm.PT.58.30682575 (TIMP1);
Mm.PT.58.8800692 (MMP7); Mm.PT.58.31508589 (TSP2)) (IDT,
Castenaso, Italy Biosystems) and TaqMan Gene Expression Assay
(Mm00516023_m1 (CCN2); Mm00447087_m1 (ICAM1); Mm0049
2632_m1 (IGFBP2); Mm01192931_g1 (PLG)) (Applied Biosystems),
normalized against the geometric median of GAPDH (Mm9999
9915_g1) and b-actin (Mm.PT.53a.3177) and expressed as 2-DDCT.
Study design and statistical analysis
This study adheres to the guidelines to the Reporting Recommenda-
tions for Tumor Marker Prognostic Studies (REMARK; http://www.
equator-network.org/reporting-guidelines/reporting-recommenda
tions-for-tumour-marker-prognostic-studies-remark/) (McShane et al,
2005). The experiments conformed to the principles set out in the
WMA Declaration of Helsinki and the Department of Health and
Human Services Belmont Report.
Patients
A two-phase design was used to identify the most promising
biomarkers associated with PDAC; as a secondary objective, the
statistical association between the most promising individual
biomarkers and pancreatitis was established. In the first exploratory
phase, biomarkers from a small sample of PDAC patients and
healthy individuals were screened. In the second confirmatory
phase, screened biomarkers were evaluated from a larger indepen-
dent sample of PDAC patients, pancreatitis patients, and healthy
individuals. Patients with PDAC were matched by sex at a 1:1 ratio
to healthy individuals. The statistical procedures applied to each
phase are explained as follows:
First exploratory phase
Variable clustering was used to identify subsets of biomarkers show-
ing an association with PDAC. It was applied in order to control the
type I and II error rates with regard to univariate analysis of individ-
ual biomarkers.
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Biomarkers were processed in four steps:
1 Screen out the candidate biomarkers with more than 10% of
value missing (outBks).
2 Apply a principal components-based clustering method (Black
& Watanabe, 2011) to the remaining variables with a 60%
explained locus variance threshold.
3 Test cluster scores for PDAC association in a simple logistic
regression framework.
4 Test singular outBks for PDAC association in a simple logistic
regression framework.
In case of complete or almost-complete separation in the univari-
able logistic regression models, the Wilcoxon rank-sum test to test
cluster scores or outBks for PDAC association was used. A P-value
< 0.10 was taken as indicating a significant association between
clusters or outBks and PDAC; only clusters or outBks reaching
statistical significance were evaluated in the confirmatory phase.
Second confirmatory phase
Screened biomarkers were tested for their association with PDAC in
univariate analysis using a logistic regression model stratified by
sex; a P-value < 0.01 was taken as confirming a significant associa-
tion between an individual biomarker and PDAC. A multivariable
logistic regression model adjusted for age effect was evaluated in
order to confirm the significant association (i.e., P-value < 0.01)
between each selected biomarker and PDAC. As a secondary analy-
sis, the statistical association between biomarkers and pancreatitis
was investigated. ROC analysis was used to test the power of
screened biomarkers to discriminate between PDAC, pancreatitis,
and controls. A multivariable logistic regression model was also
developed to improve the discovery power of CA19.9. A forward
selection procedure including CA19.9 in every model was used.
A prospective power analysis was performed to determine the
sample size of the confirmatory phase. Using a control-to-case ratio
of 1:1, 248 patients were necessary to detect relative odds per stan-
dard deviation unit equal to 1.61 with an overall two-sided alpha
level of 0.01 and power of 0.80. The Shieh–O’Brien approximation
was used for power calculations. Assuming an attrition rate of 5%,
262 cases were enrolled.
Statistical analysis was done using SAS version 9.2 (SAS Insti-
tute, Cary, NC, USA); the SAS programming code used for the ortho-
blique principal components-based clustering approach was
reported by Black and Watanabe (2011).
Mouse models
The statistical significance of the differences in plasma biomarker
levels was assessed with one-way ANOVA (GEM models) or two-
way ANOVA (PDAC-PDX models) followed by Tukey’s multiple
comparison test. The correlation of biomarker levels with tumor
volume was assessed using the Pearson correlation coefficient test.
A P-value < 0.05 was considered significant. Statistical analysis was
performed using GraphPad Prism version 7 software (GraphPad, La
Jolla, CA).
Expanded View for this article is available online.
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